|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Fluvastatin]] |
| {{fluvastatin}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Drug Interactions==
| |
| | |
| ===Cyclosporine===
| |
| | |
| [[Cyclosporine ]]coadministration increases fluvastatin exposure. Therefore, in patients taking [[cyclosporine]], therapy should be limited to LESCOL 20 mg twice daily [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. | |
| | |
| ===Fluconazole===
| |
| | |
| Administration of fluvastatin 40 mg single dose to healthy volunteers pre-treated with [[fluconazole]] for 4 days results in an increase of fluvastatin exposure. Therefore, in patients taking [[fluconazole]], therapy should be limited to LESCOL 20 mg twice daily [see Clinical Pharmacology (12.3)].
| |
| | |
| ===Gemfibrozil===
| |
| | |
| Due to an increased risk of [[myopathy]]/[[rhabdomyolysis]] when HMG-CoA reductase inhibitors are coadministered with [[gemfibrozil]], concomitant administration of LESCOL/LESCOL XL with [[gemfibrozil]] should be avoided.
| |
| | |
| ===Other Fibrates===
| |
| | |
| Because it is known that the risk of [[myopathy]] during treatment with HMG-CoA reductase inhibitors is increased with concurrent administration of other fibrates, LESCOL/LESCOL XL should be administered with caution when used concomitantly with other [[fibrates ]][see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
| |
| | |
| ===Niacin===
| |
| | |
| The risk of skeletal muscle effects may be enhanced when LESCOL is used in combination with lipid-modifying doses (≥1 g/day) of [[niacin]]; a reduction in LESCOL dosage should be considered in this setting [see Warnings and Precautions (5.1)].
| |
| | |
| ===Glyburide===
| |
| | |
| Concomitant administration of fluvastatin and glyburide increased glyburide exposures. Patients on concomitant therapy of glyburide and fluvastatin should continue to be monitored appropriately [see Clinical Pharmacology (12.3)].
| |
| | |
| ===Phenytoin===
| |
| | |
| Concomitant administration of fluvastatin and phenytoin increased phenytoin exposures. Patients should continue to be monitored appropriately when fluvastatin therapy is initiated or when fluvastatin dose is changed [see Clinical Pharmacology (12.3)].
| |
| | |
| ===Warfarin===
| |
| | |
| Bleeding and/or increased prothrombin times have been reported in patients taking coumarin anticoagulants concomitantly with other HMG-CoA reductase inhibitors. Therefore, patients receiving warfarin-type anticoagulants should have their prothrombin times closely monitored when fluvastatin sodium is initiated or the dosage of fluvastatin sodium is changed.
| |
| | |
| ===Colchicine===
| |
| | |
| Cases of [[myopathy]], including [[rhabdomyolysis]], have been reported with fluvastatin coadministered with [[colchicine]], and caution should be exercised when prescribing fluvastatin with [[colchicine]].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = LESCOL (FLUVASTATIN SODIUM) CAPSULE LESCOL XL (FLUVASTATIN SODIUM) TABLET, EXTENDED RELEASE [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8a1823e7-26fb-4858-bac7-9e152e5ea16a | publisher = | date = | accessdate = 12 February 2014 }}</ref>
| |
| | |
| ==References==
| |
| | |
| {{Reflist|2}}
| |
| | |
| {{Statins}}
| |
| | |
| [[Category:Statins]]
| |
| [[Category:Diols]]
| |
| [[Category:Indoles]]
| |
| [[Category:Carboxylic acids]]
| |
| [[Category:Organofluorides]]
| |
| [[Cardiovasular Druf]]
| |
| [[Drug]]
| |